Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sarcoma | Preclinical | GB | 18 Nov 2022 |